Processing

Please wait...

Settings

Settings

Goto Application

1. WO2005060375 - METHODS OF THERAPY AND DIAGNOSIS USING TARGETING OF CELLS THAT EXPRESS KILLER CELL IMMUNOGLOBULIN-LIKE RECEPTOR-LIKE PROTEIN

Publication Number WO/2005/060375
Publication Date 07.07.2005
International Application No. PCT/US2004/011171
International Filing Date 13.04.2004
Chapter 2 Demand Filed 18.10.2004
IPC
C07H 21/02 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
21Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
02with ribosyl as saccharide radical
CPC
A61K 2039/505
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
505comprising antibodies
A61K 38/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
A61K 47/6849
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
50the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
51the non-active ingredient being a modifying agent
68the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
6835the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
6849the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
A61K 48/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
48Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
A61K 51/1027
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
51Preparations containing radioactive substances for use in therapy or testing in vivo
02characterised by the carrier ; , i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
04Organic compounds
08Peptides, e.g. proteins ; , carriers being peptides, polyamino acids, proteins
10Antibodies or immunoglobulins; Fragments thereof ; , the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
1027against receptors, cell-surface antigens or cell-surface determinants
A61P 35/02
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
02specific for leukemia
Applicants
  • NUVELO, INC. [US]/[US] (AllExceptUS)
  • EMTAGE, Peter, C.R. [CA]/[US] (UsOnly)
Inventors
  • EMTAGE, Peter, C.R.
Agents
  • POLIZOTTO, Renee
Priority Data
10/727,01202.12.2003US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) METHODS OF THERAPY AND DIAGNOSIS USING TARGETING OF CELLS THAT EXPRESS KILLER CELL IMMUNOGLOBULIN-LIKE RECEPTOR-LIKE PROTEIN
(FR) PROCEDES DE THERAPIE ET DE DIAGNOSTIC REPOSANT SUR LE CIBLAGE DE CELLULES QUI EXPRIMENT UNE PROTEINE DU TYPE RECEPTEUR DE TYPE IMMOGLOBULINE DE CELLULE TUEUSE.
Abstract
(EN)
Certain cells, including types of cancer cells such as KIRHy1, are capable of expressing KIRHy1 mRNA. Targeting using KIRHy1 polypeptides, nucleic acids encoding for KIRHy1 polypeptides and anti-KIRHy1 antibodies provides a method of killing or inhibiting that growth of cancer cells that express the KIRHy1 protein. Methods of therapy and diagnosis of disorders associated with KIRHy1 protein-expressing cells, such as acute myelogenous leukemia (AML), are described.
(FR)
Sachant que certaines cellules, y compris des types de cellules cancéreuses comme KIRHy1 sont capables d'exprimer de l'ARNm de KIRHy1, le ciblage reposant sur des polypeptides KIRHy1, des acides nucléiques qui codent ces polypeptides et des anticorps anti-KIRHy1 constitue un procédé de destruction ou d'inhibition de la croissance cancéreuse qui exprime la protéine KIRHy1. L'invention concerne également des procédés de thérapie et de diagnostic des troubles associés aux cellules exprimant ladite protéine KIRHy1, comme les cellules de la leucémie myélogène aiguë.
Latest bibliographic data on file with the International Bureau